DK2099796T3 - Aza-indolyl-forbindelser og fremgangsmåder for anvendelse - Google Patents
Aza-indolyl-forbindelser og fremgangsmåder for anvendelseInfo
- Publication number
- DK2099796T3 DK2099796T3 DK07854844.3T DK07854844T DK2099796T3 DK 2099796 T3 DK2099796 T3 DK 2099796T3 DK 07854844 T DK07854844 T DK 07854844T DK 2099796 T3 DK2099796 T3 DK 2099796T3
- Authority
- DK
- Denmark
- Prior art keywords
- aza
- methods
- indolyl compounds
- indolyl
- compounds
- Prior art date
Links
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86805506P | 2006-11-30 | 2006-11-30 | |
| US91762007P | 2007-05-11 | 2007-05-11 | |
| US94474307P | 2007-06-18 | 2007-06-18 | |
| PCT/US2007/085962 WO2008067481A1 (en) | 2006-11-30 | 2007-11-29 | Aza-indolyl compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2099796T3 true DK2099796T3 (da) | 2011-09-05 |
Family
ID=39169665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07854844.3T DK2099796T3 (da) | 2006-11-30 | 2007-11-29 | Aza-indolyl-forbindelser og fremgangsmåder for anvendelse |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7855216B2 (da) |
| EP (1) | EP2099796B1 (da) |
| JP (1) | JP5211063B2 (da) |
| AR (1) | AR064031A1 (da) |
| AT (1) | ATE511509T1 (da) |
| AU (1) | AU2007325123B2 (da) |
| CA (1) | CA2672327A1 (da) |
| CL (1) | CL2007003444A1 (da) |
| DK (1) | DK2099796T3 (da) |
| PE (1) | PE20081354A1 (da) |
| PL (1) | PL2099796T3 (da) |
| PT (1) | PT2099796E (da) |
| TW (1) | TW200829586A (da) |
| WO (1) | WO2008067481A1 (da) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2297070A2 (en) * | 2008-07-03 | 2011-03-23 | Bayer Schering Pharma Aktiengesellschaft | Compounds and processes for production of radiopharmaceuticals |
| JP5651125B2 (ja) | 2008-12-10 | 2015-01-07 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異 |
| ES2576061T3 (es) | 2010-02-25 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF |
| EP2545187B1 (en) | 2010-03-09 | 2018-09-05 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
| MX342879B (es) | 2010-07-30 | 2016-10-14 | Oncotherapy Science Inc * | Derivados de quinolina e inhibidores de cinasa de cremallera de leucina embrionica materna que los contienen. |
| WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| TW201414734A (zh) | 2012-07-10 | 2014-04-16 | Takeda Pharmaceutical | 氮雜吲哚衍生物 |
| EP2916859B1 (en) | 2012-11-02 | 2017-06-28 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
| UA111925C2 (uk) | 2012-12-11 | 2016-06-24 | Федора Фармасьютікалз Інк. | БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| US20170114323A1 (en) | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| WO2017180581A1 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| US10988483B2 (en) | 2017-05-19 | 2021-04-27 | Nflection Therapeutics, Inc. | Fused heteroaromatic-aniline compounds for treatment of dermal disorders |
| EP3624796B1 (en) | 2017-05-19 | 2025-03-19 | NFlection Therapeutics, Inc. | Pyrrolopyridine-aniline compounds for treatment of dermal disorders |
| EP3679159A1 (en) | 2017-09-08 | 2020-07-15 | H. Hoffnabb-La Roche Ag | Diagnostic and therapeutic methods for cancer |
| WO2019158579A1 (en) | 2018-02-13 | 2019-08-22 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| CA3120337A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Naphthyridinone-aniline compounds for treatment of dermal disorders |
| MA55141A (fr) | 2018-11-20 | 2021-09-29 | Nflection Therapeutics Inc | Composés cyanoaryl-aniline pour le traitement d'affections de la peau |
| WO2020106305A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Thienyl-aniline compounds for treatment of dermal disorders |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| CA3238962A1 (en) | 2021-11-23 | 2023-06-01 | Nflection Therapeutics, Inc. | Formulations of pyrrolopyridine-aniline compounds |
| IL313821A (en) * | 2022-01-28 | 2024-08-01 | Insilico Medicine Ip Ltd | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP1) inhibitors and their uses |
| EP4488276A1 (en) * | 2022-03-04 | 2025-01-08 | Samjin Pharmaceutical Co., Ltd. | Novel heterocyclic compound and pharmaceutical composition comprising same |
| WO2024033381A1 (en) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition of tcf4/itf2 in the treatment of cancer |
| WO2025026383A1 (en) * | 2023-08-02 | 2025-02-06 | Insilico Medicine Ip Limited | Crytsalline forms of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof |
| WO2025100940A1 (ko) * | 2023-11-07 | 2025-05-15 | 보로노이 주식회사 | 헤테로아릴 유도체 화합물 및 이의 용도 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| AU2003239150A1 (en) | 2002-04-23 | 2003-11-10 | Aventis Pharmaceuticals Inc. | 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo |
| US6929411B2 (en) * | 2003-09-03 | 2005-08-16 | Hewlett-Packard Development Company, L.P. | Selectable control of raster image processor |
| GB0412914D0 (en) * | 2004-06-10 | 2004-07-14 | Oxagen Ltd | Compounds |
| PE20060526A1 (es) * | 2004-06-15 | 2006-07-13 | Schering Corp | Compuestos triciclicos como antagonistas de mglur1 |
| US7598259B2 (en) * | 2004-06-15 | 2009-10-06 | Schering Corporation | mGluR1 antagonists as therapeutic agents |
| DE102005013621A1 (de) * | 2005-03-24 | 2006-09-28 | Curacyte Discovery Gmbh | Substituierte 2-Aryl(Hetaryl)-5-aminothieno[2,3-d]pyrimidin-6-carbonsäureamide, Verfahren zu ihrer Herstellung und Verwendung als Pharmazeutika |
| AR070127A1 (es) * | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
-
2007
- 2007-11-29 PL PL07854844T patent/PL2099796T3/pl unknown
- 2007-11-29 TW TW096145474A patent/TW200829586A/zh unknown
- 2007-11-29 DK DK07854844.3T patent/DK2099796T3/da active
- 2007-11-29 US US11/947,656 patent/US7855216B2/en not_active Expired - Fee Related
- 2007-11-29 CA CA002672327A patent/CA2672327A1/en not_active Abandoned
- 2007-11-29 EP EP07854844A patent/EP2099796B1/en active Active
- 2007-11-29 PT PT07854844T patent/PT2099796E/pt unknown
- 2007-11-29 AT AT07854844T patent/ATE511509T1/de active
- 2007-11-29 AU AU2007325123A patent/AU2007325123B2/en not_active Ceased
- 2007-11-29 JP JP2009539490A patent/JP5211063B2/ja not_active Expired - Fee Related
- 2007-11-29 PE PE2007001679A patent/PE20081354A1/es not_active Application Discontinuation
- 2007-11-29 AR ARP070105307A patent/AR064031A1/es unknown
- 2007-11-29 WO PCT/US2007/085962 patent/WO2008067481A1/en not_active Ceased
- 2007-11-29 CL CL200703444A patent/CL2007003444A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20081354A1 (es) | 2008-11-14 |
| US20080242655A1 (en) | 2008-10-02 |
| US7855216B2 (en) | 2010-12-21 |
| PL2099796T3 (pl) | 2011-10-31 |
| TW200829586A (en) | 2008-07-16 |
| JP5211063B2 (ja) | 2013-06-12 |
| AU2007325123B2 (en) | 2012-12-13 |
| JP2010511626A (ja) | 2010-04-15 |
| PT2099796E (pt) | 2011-09-06 |
| EP2099796A1 (en) | 2009-09-16 |
| AU2007325123A1 (en) | 2008-06-05 |
| WO2008067481A1 (en) | 2008-06-05 |
| EP2099796B1 (en) | 2011-06-01 |
| CL2007003444A1 (es) | 2008-06-27 |
| AR064031A1 (es) | 2009-03-04 |
| ATE511509T1 (de) | 2011-06-15 |
| CA2672327A1 (en) | 2008-06-05 |
| HK1135099A1 (en) | 2010-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2099796T3 (da) | Aza-indolyl-forbindelser og fremgangsmåder for anvendelse | |
| ATE531720T1 (de) | Aza-benzofuranylverbindungen und anwendungsverfahren dafür | |
| EP2094085A4 (en) | ANTI-CHOLESTEROLMIC COMPOUNDS AND METHODS OF USE | |
| DK1940839T3 (da) | Pyridopyrimidione Inhibitors of P13Ka | |
| DK1924577T3 (da) | Substituerede benzimidazoler og fremgangsmåder til fremstilling | |
| DK2001556T3 (da) | Thioninium-forbindelser og anvendelse deraf | |
| CY2014012I2 (el) | Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης | |
| IL189771A0 (en) | Raf inhibitor compounds and methods of use thereof | |
| ZA200710969B (en) | Raf inhibitor compounds and methods of use thereof | |
| NO345061B1 (no) | Anvendelse av DPP-IV inhibitorer | |
| DK1802872T3 (da) | Rörledning | |
| EP2023718A4 (en) | CREATINLIGATE COMPOUNDS AND APPLICATION METHOD THEREFOR | |
| ZA200802585B (en) | Pyridopyrimidinone inhibitors of Pl3Kα | |
| IL197060A0 (en) | Aza-benzothiophenyl compounds and methods of use | |
| DK2152748T3 (da) | Anti-Notch1-NRR-antistoffer og fremgangsmåder til anvendelse deraf | |
| HRP20150003T1 (xx) | Sastavi inhibitora dpp-iv | |
| DK2147315T3 (da) | Diabetesrelaterede biomarkører og fremgangsmåder til anvendelse deraf | |
| DK2118140T3 (da) | Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf | |
| DK2069467T3 (da) | Adskillende sammensætninger og fremgangsmåder til anvendelse | |
| DK2079485T3 (da) | Phenylpropionamidforbindelser og anvendelsen deraf | |
| DK3338790T3 (da) | Oligopeptid-forbindelser og anvendelser deraf | |
| EP2079544A4 (en) | ARSENIC ABSORBENT COMPOSITION AND METHODS OF USE | |
| ZA200808017B (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
| DK2107373T3 (da) | Analysechip og analysefremgangsmåde | |
| IL185309A0 (en) | Isoqunoline compounds and methods of use thereof |